Ulcerations of the Oral Cavity

TITLE: Ulcerations of the Oral Cavity
SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology
DATE: March 31, 2009
RESIDENT PHYSICIAN: David Gleinser, MD
FACULTY PHYSICIAN: Susan McCammon
SERIES EDITORS: Francis B. Quinn, Jr., MD
ARCHIVIST: Melinda Stoner Qui= nn, MS(ICS)

"This material was prepared by resid= ent physicians in partial fulfillment of educational requirements established f= or the Postgraduate Training Program of the UTMB Department of Otolaryngology/= Head and Neck Surgery and was not intended for clinical use in its present form.= It was prepared for the purpose of stimulating group discussion in a conference setting. No warranties, either express or implie= d, are made with respect to its accuracy, completeness, or timeliness. The material does not necessarily reflect the current or past opinions of members of the UTMB faculty and should not be used for purposes of diagnosis or treatment without consulting appropriate literature sources and informed professional opinion."

Infection Causing Oral Ulceration

There are many infectious organisms that can lea= d to oral ulceration, but for the purpose of this presentation we will only disc= uss a few of the organisms. Be awar= e that many fungal organisms can lead to oral ulceration, so should be included in ones differential diagnosis when dealing with an immunocomprimised patient.=

Herpes Simplex Virus

Herpes Simplex Virus is a DNA virus that is part= of the Herpesviridae family. HSV= -1 is considered the most common subtype when discussing infection of the oral ca= vity, but HSV-2 has been known to cause oral infection as well. The virus is transmitted by direct contact with body fluid. The average incubation time is about 7 days, but can be anywhere from 1-26 days. Once the primary infect= ion has resolved, the virus migrates along the periaxonal sheath of the trigemi= nal nerve to the trigeminal ganglion. This is where it lies dormant until it is reactivated

The primary infection caused by HSV in the oral = cavity is termed herpetic gingivostomatitis. It presents with multiple small vesicles involving many oral cavity sites. The vesicles rupture i= n 24 hours leaving ulcerations. As= this process occurs, new crops of vesicles continue to appear and ulcerate. The ulcerations typically heal ove= r a 7-14 day course. Accompanying= the vesicles, one can also experience fever, arthralgia, malaise, headache, and= cervical lymphadenopathy. Of note, the= greatest infectivity rate occurs when the vesicles rupture. This rate decreases as the ulcers = crust over.

The secondary infection is termed reactivation.<= span style=3D'mso-spacerun:yes'> This occurs in roughly 16-45% of patients who actually have the virus. Triggers to reactivation include UV light, stress, infection, and im= munosuppresion. One typically sees a crop of vesic= les erupt on the mucocutaneous junction of the lips, hard palate, and other attached gingiva. Prior to the appearance of the vesicles, patients may complain of a prodrome of tingling, itching, or burning. The dise= ase usually runs its course in 7-14 days.

For the diagnosis of HSV it is recommended that = fluid be obtained from an unruptured vesicle for analysis as this fluid is more likely to obtain the virus. T= here is a much lower yield if attempting to obtain specimens from a crusted lesi= on. From the fluid, most labs will use= PCR to identify the virus as it tends to be faster than cultures. However, cultures can also be sent= . Serologic testing is another metho= d for diagnosis HSV. This typically involves the use of ELISA or Western blot.= Western blot is very accurate, but time consuming.

The treatment of HSV related infection begins wi= th supportive care; antipyretics, analgesics, and hydration. Valacyclovir, Famciclovir, and Acy= clovir are drugs typically used to combat HSV.&nb= sp; They work by inhibiting viral DNA polymerase. This helps to suppress and control symptoms, but does not cure the infection.= Valacyclovir and Famciclovir have become more popular due to a better bioavailability than Acyclovir. If the health care provider can catch the disease in the prodrome state, topic= al 5% acyclovir cream for 1 week has shown to shorten the course or completely ab= ort reactivation altogether.

Varicella Zoster

The Varicella Zoster virus is also part of the Herpesviridae family. Its pri= mary infection is termed chicken pox while its secondary infection is shingles.<= span style=3D'mso-spacerun:yes'> This virus is typically spread by respiratory droplets and less commonly by direct contact. The incubation time is roughly 2 w= eeks.

Following incubation, the patient develops a fev= er, headaches, malaise, and a rash. The vesicles associated with the rash turn to pustules that then rupture leaving ulcerations. These ulceration= s then scab over. In the oral cavity= , the lesions tend to involve the buccal mucosa and hard palate and have been described as having the appearance of an aphthous ulcer.

Typically, all that is needed for the diagnosis = is the clinical picture. However, on= e may utilize direct florescent antibody testing on a smear obtained from a lesion. This method is rapid = and highly sensitive and specific. ELISA and PCR are also options.

The vaccine against Varicella Zoster is the best= way to prevent or lessen the severity of the infection. If an infection does occur, treatm= ent is aimed at supportive care. If a severe form of the disease occurs, treatment with Valacyclovir or Acyclovir= is indicated. One must be sure t= o monitor for secondary bacterial infections.

Shingles is considered the secondary form of Var= icella Zoster. The disease presents = first with a prodrome of burning or pain over a dermatome; most often V3. Following this, a maculopapular ra= sh develops over that dermatome. Vesicles soon follow, that then turn to pustules. These pustules rupture forming ulcerations that then crust over. If there is going to be oral involvement, it is more likely going to occur after skin involvement. As with the primary infection, Shingles can usually be diagnosed with the clin= ical picture. If more testing is required, the modalities utilized are the same as those used for the primary infection. All that is = typically required for the treatment of Shingles is supportive care. The severe forms can be treated wi= th Valacyclovir or Acyclovir.

Candidiasis

Candidiasis is the n= ame given to the fungal infection caused by any of the Candida species. These organisms are part of the no= rmal oral flora in 40-65% of patients. Infections are noted to occur when a patient is in an immunocomprimi= sed state, suffers oral trauma, or has recently used antibiotics. Three forms of candidiasis a= re pseudomembranous candidiasis (thrush), atrophic candidiasis, and mucocutane= ous candidiasis.

Thrush is the most common form of candidiasis encountered. It appears as a whitish plaque that can be scrapped off to reveal a “beefy” red base or ulceration that is tender to palpation. Acute atrophic candidiasis typical= ly appears as an erythematous patch on the lateral aspect of the tongue. This form usually occurs after ant= ibiotic use, and may precede thrush. = There are two subtypes of atrophic candidiasis, chronic atrophic candidiasis and angular chelitis. In both for= ms, poor denture use is a common finding. Poor fitting dentures not only can lead to tissue damage and breakdo= wn of the tissue it is in direct contact with, but can also cause saliva to po= ol in the oral commisures. This = leads to tissue irritation and opportunistic infection. Mucocutaneous candidiasis is the m= ost severe form of infection caused by the Candida species. Patients are usually very ill prio= r to presenting with this form. Th= e key to this disease is its diffuse involvement; oral cavity, lips, skin, other mucosal surfaces. The oral ca= vity involvement reveals lesions typical of pseudomembranous candidiasis, but more diffuse.<= span style=3D'mso-spacerun:yes'> A familial form of this disease ex= ists. It is termed Chronic Mucocutaneous= Candidiasis. It is an autosomal recessive disea= se in which cell-mediated immunity is impaired leaving patients more susceptible = to infection.

The diagnosis of candidiasis starts with the cli= nical picture. Along with this, microscopic examination utilizing a KOH prep of scrapings obtained from a lesion will reveal pseudohyphae, hyphae, and yeast all present on the same slide. A culture or serum (1<= span class=3DGramE>,3)β-D-glucan detection assay can also be utilize= d if the diagnosis is unclear.

In mild, acute forms of the disease all that is = usually needed for treatment is topical Nystatin.&= nbsp; If the disease is mild, but chronic the addition of Clotrimazole tro= ches to the topical Nystatin has shown improvement. If however, the disease is refract= ory or the patient is immunocomprimised WITHOUT signs of systemic involvement one should consider adding oral Fluconazole.&n= bsp; For severe, systemic forms Amphotericin B with or without Fluconazol= e is the treatment of choice.

Actinomycosis

Actinomyces are a gr= oup of anaerobic, gram positive rods. They are = typically found in the oral flora, and are considered opportunistic. Patients who suffer from this dise= ase usually are immunocomprimised or have a history of trauma or poor oral hygi= ene. It is an uncommon disease affecting roughly 1 in 300,000 people. = Most often, patients present with a palpable neck mass. Overlying this neck mass is a purp= lish discoloration. Sinus tracts a= s well as granulomatous, supparative lesions of the larynx, GI tract, or lungs have been reported. The diagnosis = is made through microscopic examination showing sulfur granules and gram posit= ive, branching, filamentous rods. Culture usually takes 1-2 weeks.&nb= sp; Treatment of the disease is aimed at surgical debridement and antibiotics. The recommended = dosing is IV PCN G for 2-6 weeks followed by oral PCN for 3-6 months.

Autoimmune Causes of Oral Ulceration

There are a number of autoimmune diseases that c= an lead to oral ulceration. Many= of these have similar findings on exam, and so a more complete history and physical along with laboratory testing is needed to make a diagnosis. Be aware that infection can be ove= rlying the true cause of the illness.

Lupus Erythematous

Lupus Erythematous (LE) is an autoimmune (AI) di= sease with an incidence of roughly 40-50 per 100,000 people. It can be broken into two main typ= es, Discoid LE, and Systemic LE. Discoid = LE is a disease involving the skin and oral cavity without visceral involvement.<= span style=3D'mso-spacerun:yes'> Systemic LE involves the skin, oral cavity, and visceral organs. = Oral involvement is seen more often in Systemic LE; 40% of cases vs. 25% of cases seen in Discoid LE.

The oral disease presents as erythematous plaque= s or erosions that can evolve into ulcerations.= These lesions have a white keratotic striae radiating from the margi= ns, and involve the buccal mucosa, gingiva, labial mucosa, and vermillion borde= r. Other findings associated with LE = are the malar rash, discoid rash, photosensitivity, arthritis, seizures, and gl= omerulonephritis.

Diagnosis takes into account many factors that i= nclude the clinical appearance, immunofluorescence testing of antibody-antigen complex, and the presence of ANA and anti-dsDNA antibody. The treatment of the oral manifest= ations is aimed at good oral hygiene along with topical steroids. If the disease is severe, systemic modalities such as steroids with or without cytotoxic agents (Cyclophospham= ide and Azathioprine) are needed. Methotrexate can be used if the disease is resistant to steroids.

Pemphigoid

Pemphigoid is actual= ly a broader name given to a group of rare diseases. The incidence of these diseases is reported to affect less than 200,000 people in the United States. Three diseases that fall under the category of pemphigoid are bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris.

Bullous pemphigoid is caused by antibodies direc= ted at the epithelial basement membrane eliciting an inflammatory response. The lesions in this disease appear= as vesicles that can then rupture to form open ulcerations. Oral involvement is seen in 40% of= cases, but typically follows skin involvement.&nb= sp; The disease is self-limiting, but often recurs. The diagnosis is made by examining biopsy specimens with immunofluorescence.&= nbsp; This shows deposits of IgG and C₃ in a linear fashion alo= ng the epithelial basement membrane. Treatment requires systemic steroids with or without cytotoxic agents. Topical steroids are used to help = improve lesions. When the patient sho= ws resistance to treatment, the use of IV immunoglobulin should be considered. Cicatricial pemph= igoid can be discussed in relation to bullous pemphigoid since the mechanism of injury is the same. The major difference between the two comes with oral involvement. Cicatricial pemphigoid has oral involvement in 85% of cases, and may be the only presentation of the disease.

Pemphigus vulgaris is caused by antibodies direc= ted at intercellular bridges. This l= eads to separation of the cells in the epithelial layer resulting in very thing walled bullae. The lesions se= en in this disease appear as ulcerations with a grey membranous covering. They arise in the oral cavity firs= t, and then appear on the skin, in contrast to bullous pemphigoid. When the mucosa around a lesion is scraped, it likely will exhibit slothing.&= nbsp; This is the Nikolsky sign. &nb= sp; Diagnosis of pemphigus vulgaris is made by microscopic examination of biopsy specimens. These speci= mens show a “tombstone” appearance along with Tzanck cells (free squamous cells forming a spherical shape). Direct immunofluorescence will show IgG against cell-cell adhesion junctions. The treatment of this disease requ= ires the use of high dose systemic steroids along with cytotoxic agents. Plasmapheresis has also been utili= zed with good results. The progno= sis of this disease is typically poor. Untreated, pemphigus vulgaris will result in death in 2-5 years. However, with treatment, 10-15% of patients will die due to complications arising from long-term immunosuppres= ion.

Erythema Multiforme

The et= iology of erythema multiforme (EM) is unclear. However, it is thought to be the r= esult of a hypersensitivity reaction to an infectious agent or drug exposure. The incidence is reported as affec= ting anywhere from 0.1-1% of the population.&nb= sp; There are three major types; erythema multiforme minor, erythema multiforme major/Steven-Johnson syndrome, and toxic epidermal necrolysis.

Erythema multiforme minor is the most common type. It is typically the res= ult of a pathogen exposure (HSV and Mycoplasma species). In nearly 50% of cases, the diseas= e will begin with a flu-like illness 1-14 days prior to development of a rash. The rash that follows appears as “target lesions” on the trunk and/or palms of hands and soles of feet. In 25% of cases, ulcera= tions of the oral cavity occur. Ove= rall, less than 10% of the total body surface is involved. The disease is self-limiting, and typically resolves in 2-4 weeks. The diagnosis is purely clinical while treatment is mainly supportive as the disease is self-limiting. Top= ical or systemic steroids can be considered if lesions are symptomatic. In addition, topical and/or oral antibiotics should be given to prevent secondary bacterial infection.

Steven-Johnson Syndrome is the diagnosis when gr= eater than 10%, but less than 30% of the total body surface is involved with lesi= ons. The lesions tend to involve more m= ucosal surfaces, and are described as being more painful. Oral involvement with hemorrhagic, ulcerative lesions is common. This form of EM is more fatal due to the greater body surface involvement leadin= g to greater loss of fluid and secondary bacterial infections.

Toxic epidermal necrolysis<= /span> is the wo= rst form of EM. Its lesions invol= ve greater than 30% of the total body surface. Nearly 80% of cases are related to= a drug exposure. This disease result= s in full thickness detachment of epidermis leading to near total or total necrosis.<= span style=3D'mso-spacerun:yes'> The most common mucosal surface in= volved is the oral cavity.

The diagnosis of Steven-Johnson syndrome and tox= ic epidermal necrolysis is made by clinical observation. Treatment involves systemic steroi= ds, topical and systemic antibiotics, fluid and electrolyte replacement, and cl= ose monitoring in an ICU setting. The more severe forms of EM have been known to compromise a patient’s airway.

Lichen Planus

Lichen Planus is a T-cell mediated disease where T-cells destroy the basal cell layer of the epidermis. It is seen with an increased incid= ence in patients with Hepatitis C. The cutaneous lesions typically appear on flexor surfaces, and can be described by the 5 P’s; purple, pruritic, planar, polygonal, papules. Roughly 70% of cases have oral involvement. The appearance o= f the oral lesion depends on the subtype of disease. The reticular form is characterize= d by the appearance of white striae on the buccal mucosa that does not scrape of= f. This is the most common form. The plaque form has lesions that resemble leukoplakia. They ar= e typically located on the dorsum of tongue or buccal mucosa. The bullous form is rare, but the = lesions appear as bullae that rupture leaving areas of ulceration. Finally, the erosive form has pain= ful, erythematous erosions.

The lesions in lichen planus have to be monitored closely as malignancy is reported to arise from them in 1-5% of cases. The cutaneous lesions typically re= solve in 6 months, but oral lesions tend to last longer, with reports of some las= ting as long as 5 years. The diagnosis is obtained by examining the clinical picture in combination with biopsying the lesions. Treatm= ent of oral lesions consists of topical steroids and Cyclosporine mouth wash. For severe disease, systemic stero= ids are needed.

Behcet’s Syndrome

Behcet’s Syndr= ome is a vasculitis believed to be secondary to a hypersensitivity reaction to HSV and/or Streptococcal antigen. It is rare in the United States with an incidence of 5/100,000 population. However, it is more common in Asia= n/Middle Eastern countries where the incidence is reported as 1/10,000 population. The disease is nearly always seen = in males, with a 16-24:1 male to female ratio. Oral ulcerations are common, and a= re very similar to aphthous ulcers in appearance. Other symptoms seen in the disease= are recurrent genital lesions, eye lesions (uveitis, retinal vasculitis), skin lesions (erythema nodosum), polyarthritis, and meningioencephalitis. The diagnosis is based solely on t= he clinical appearance. Typically, topical and systemic steroids are needed to improve lesions. Systemic steroids have been shown = to improve acute symptoms, but do not slow the progression or prevent recurren= ce of the disease.

Kawasak= i Disease

Kaw= asaki disease is a vasculitis of small and medium sized arteries affecting childr= en. The peak age of involvement is 18-= 24 months with 80% of cases occurring in children less than 5 years of age. The Incidence is 67 per 100,000 ch= ildren less than 5 years of age. The disease begins with a high grade fever that persists for more than 5 days.<= span style=3D'mso-spacerun:yes'> Without this, a diagnosis cannot be made. Soon after the fever on= set, oral involvement occurs. This= takes the form of fissuring of the lips, oral ulcerations, and a strawberry tongu= e. Three to five days after fever ons= et, an erythematous, maculopapular rash appears.&= nbsp; It starts on the palms of hands and soles of feet and soon spreads t= o the trunk. Other symptoms include= dry conjunctivitis, desquamation of the skin, cervical adenopathy, and coronary aneurysms. The coronary aneur= ysms typically appear 2-8 weeks after the main symptoms.&= nbsp; The diagnosis is made based on clinical presentation. However, echocardiography should be performed 7 days after the disease onset, and then 6-8 weeks later to deter= mine if coronary aneurysms have developed.

Treatment of Kawasaki disease includes the use of Aspirin, IV immunoglobulin, and bed rest. Aspirin is used at high doses init= ially for its anti-inflammatory action. Later, however, it is used at a lower dose for its antiplatelet effect. If not treated,= 25% of patients will develop coronary aneurysms. Compare this to only 1-10% of cases developing coronary aneurysms if treatment is started early. One can expect coronary aneurysms = to resolve over a 2 year period.

Aphthous Ulcers

Although the etiology of aphthous ulcers is not = clear, it is believed the immune system plays a role in their development. They are considered the most common cause of non-traumatic ulcerations of the oral cavity with roughly 10-20% of the population having experienced them.&nb= sp; Three classifications exist. They are minor, major, and herpetiform ulcers.

Minor aphthous ulcers are less than 1 cm in diam= eter and located typically on freely mobile oral mucosa. They appear as a well-delineated w= hite lesion with an erythematous halo. Prior to appearance, some patients report a prodrome of burning or tingling in the area of involvement. These ulcers tend to resolve in 7-10 days and almost never scar.

Major aphthous ulcers= are larger than 1 cm. They can be= found on freely mobile oral mucosa, the tongue, and palate. These ulcers tend to last much lon= ger with reports of some lasting 6 or more weeks.&n= bsp; Unlike the minor form, however, these more often scar upon healing.<= /p>

Herpetiform ulcers appear as a small, 1-3mm in diameter ulceration arising in crops of 20-200 ulcers. They are located on freely mobile = oral mucosa, the tongue, and palate. They tend to last 1-2 weeks, and are extremely painful. They are called herpetiform becaus= e the ulcerations resemble those of HSV, but there is no vesicular phase as there is in HSV lesions.

The treatment of aphthous ulcers begins with top= ical preparations. Topical Tetracy= cline solution for 5-7 days has shown good results while topical steroids have be= en shown to shorten disease duration. = Sucralfate suspension has shown to improve pain as well as shorten the disease duratio= n. Major aphthous= ulcers or more severe forms of disease tend to require systemic steroids.

Radiation/Chemotherapy Induced = Mucositis

Treatment options for head and neck cancer inclu= de the use of radiation and chemotherapy. However, one potential side effect from using these treatment modali= ties is the development of mucositis, the inflammation of mucus membranes. The incidence of radiation/chemothe= rapy induced mucositis is reported to be around 30-40% of patients receiving chemotherapy or radiation. Chemotherapy induced mucositis typically occurs within 5-10 days of starting therapy while radiation induced mucositis is seen during the 2nd week of therapy.

There are 5 phases to the overall process. First, is the initiation phase. During this phase free radicals de= velop in response to therapy leading to the initial damage. Second, message generation occurs.= During this phase transcription fa= ctors are activated. These attract inflammatory activators IL-1 and TNF-α. These inflammatory activators cause increased inflammation, dilated vessels and further tissue damage in a phas= e termed the amplification phase. The = next phase is termed the ulceration phase. Ulceration develops as a result of immune mediated tissue damage and microtrauma from speech, swallowing, and mastication. In addition to this, secondary bac= terial infections occur leading to further tissue damage. The last phase is the healing phase. During this phase, ulc= ers re-epithelialize and bacteria are destroyed. The typical disease course runs 2-3 weeks for both chemotherapy and radiation induced mucositis.

Treatment of mucositis is aimed at four areas. First, good oral hygiene must be maintained. Patients should r= inse with dilute hydrogen peroxide or sodium bicarbonate solutions. Also the use of soft tooth brushes= and sponge-tipped applicators for removing plaques/crusting is needed. The second goal of treatment is to= prevent or eradicate infection. This = is done through the use of fluoride rinses and antifungal agents. The third goal is to maintain good moisture. This can be achieved through the use of petroleum jelly and mineral oil. The last goal of therapy is pain control. The use of topical L= idocaine, Sulcralfate, and systemic pain medications can all help to accomplish this goal.

Premalignancy/Malignancy= – Presentation

An area that cannot be overlooked when discussin= g oral ulceration is malignancy. For= the purpose of this discussion only basic information will be given about this topic. The main piece of information to take away from this section is that any ulceration that fail= s to heal in 1-2 weeks should be biopsied.

Before we can discuss malignant lesions, we need= to examine some premali= gnant lesions. The first is leukoplakia. It appears as a whitish plaque that cannot be scrapped off. The incidence of malignancy arising from these lesions is anywhere from 5-20%, = so close monitoring is necessary. Microscopic examination of biopsies will reveal hyperkeratosis and atypia. One should also note that lesions = involving the lateral tongue, lower lip, and floor of mouth are more likely to progre= ss to malignancy. Another premal= ignant lesion is erythroplakia. This serious lesion appears as a red patch or macule with a soft, velvety textur= e. It requires close observation as malignant potential is extremely high.&nbs= p; Roughly 60-90% of untreated cases will undergo malignant transformation. Treatment is usually surgical excision or laser ablation.

Oral cavity cancers account for roughly 30% of a= ll head and neck cancer making it the most common site of head and neck cancer= . The symptoms/findings involved wit= h oral malignancy include non-healing ulcerations, pain, expansile lesions, trismu= s, dysphagia, odonyphagia, halitosis, numbness in lower teeth (inferior alveol= ar nerve involvement), and others. Indicators of more aggressive tumors are those tumors greater than 1 cm in size, invad= ing 4 mm or more, or exhibiting perineural, lymphatic, or vascular invasion.

Squamous cell carcinoma is most common type of c= ancer found in the oral cavity, accounting for nearly 90% of all cases. A less aggressive variant of squam= ous cell carcinoma is verrucous carcinoma.&nbs= p; It is typically located on the buccal mucosa, and appears as a warty lesion. It is rare that this = type of cancer ever metastasis or exhibits deep invasion. Basal cell carcinoma can also be f= ound in the oral cavity, but more commonly involves the upper lip. Salivary gland malignancies also a= ppear in the oral cavity with adenoid cystic carcinoma being the most common. Other malignancies involving= the oral cavity include lymphoma, sarcomas (rhabdomyosarcoma and liposarcoma mo= st commonly), and melanoma.

Necrotizing Sialometaplasia

Necrot= izing sialometaplasia is a lesion that needs to be discusse= d as it is commonly mistaken for squamous cell carcinoma. It is a non-neoplastic, inflammato= ry lesion of salivary glands thought to be the result of vascular ischemia. It is typically located on the hard palate, but can be just about anywhere in the oral cavity. It presents as a 1-3cm ulceration,= and may exhibit bony erosion. Spontaneous resolution occurs within 5 weeks, but= can take up to 9 weeks. Diagnosis= can only be made by a good incisional biopsy.&= nbsp; If there is any question about the diagnosis after biopsy, get anoth= er biopsy. Treatment is only sup= portive as these lesions resolve on their own.

Burning Mouth Syndrome

Burning mouth syndrome is included in this talk because many of the causes of oral ulceration can present initially with th= is syndrome’s clinical picture. The main symptoms seen are intense oral pain described as burning or scalding, altered taste, and xerostomia.&n= bsp; Other symptoms reported are painful mastication, jaw clenching, mult= iple mood and emotional disturbances (anxiety, irritability, depression). The pain associated is constant throughout the day, and lasts for months at a time. There are two main types, pr= imary and secondary burning mouth syndrome. These are separated on the basis of whether a cause can be found. Primary is idiopathic while secondary has an identifiable cause.

It is good to note that this syndrome is seen mo= re often in perimenopausal and postmenopausal women. A theory exists that the lack of estrogen in women who are peri- or postmenopausal leads to atrophy of the o= ral mucosa. This in turn leads to= altered nerve function as well as allowing for increased inflammation. Some other known and proposed caus= es include immunologic reactions to allergens (peanuts, benzoyl peroxide), nutritional deficiency (B vitamins, folate, iron), infectious agents (Candida species), iatrogenic causes (radiation and chemotherapy), and neurologic disorders (anxiety, depression, Diabetic neuropathy).

The prognosis isn’t great for patients suf= fering from burning mouth syndrome as only 3% of patients with the primary type wi= ll have full resolution. However= , 50-60% of patients will improve. Tre= atment depends on the type. For the primary type, many different treatment modalities have been attempted, but nothing is agreed upon as the main treatment. Treatments that have shown some improvement include SSRIs, benzodiazepines, TCAs, psychotherapy, oral Lidoc= aine, neuropathic analgesics, and systemic pain medications. The treatment of secondary burning= mouth syndrome is aimed at treating the underlying cause.

Conclusion

In conclusion, there are many causes of oral ulcerations, and this discussion only mentioned a few of them. Many of the clinical findings overl= ap between the different disease states, thus attention to detail is important (good history and physical) to arrive at a diagnosis. It is very important to make a definitive diagnosis as treatment can vary drastically; Necrotizing sialometaplasia vs. invasive squamous cell carcinoma of the hard palate. Remember, if an ulceration has not healed in 1-2 weeks, biopsy it.

Bibliography

1.&n= bsp; Bailey, Byron J., et al., eds. Head & Neck Surgery – Otolaryngology. 4^th ed. 2 vols. Philadelphia: Lip= pincott Williams & Wilkins, 2006.

2.&n= bsp; Pasha, Raza, Otolaryngology – Head and Neck Surgery. 2^nd ed. San Diego: Plural Publishing Inc., 2006.

3.&n= bsp; Family Practice Notebook. Acute Necrotizing Ulcerat= ive Gingivitis. [Online] Available: http://www.fpnotebook.com/DEN/ID/ActNcrtzng= UlcrtvGngvts.htm, 2008.

4.&n= bsp; Vaughn, John A. “Management of Acute Orofacial Pain Syndromes.” The Journal of Urgent Care Medicine. [Online] Available: http://www.jucm.com/2007-feb/clinical1.shtml, Feb. 2007.

5.&n= bsp; Svirsky, John, and John Fantasia. “Necrotizing Sialometaplasia.” eMedicine from WebMD. [Online] Available: http://em= edicine.medscape.com/article/1077574, Oct. 2008.

6.&n= bsp; Spiller, Martin S.= Cold Sores (herpes labialis). [Online] Available: http://www.doctors= piller.com/cold_sores.htm, 2006.

7.&n= bsp; Spiller, Martin S.= Acute necrotizing ulcerative gingivitis. [Online] Available: http://= www.doctorspiller.com/anug.htm, 2006.

8.&n= bsp; Nguyen, Minh. Primary Herpes Simplex Infection. Soft Dental. [Online] Available: http://www.softdental.com/diseases/Primary_Herp= es_Simplex_HSV_Infection.html, 2005.

9.&n= bsp; Scully, Crispian. “Candidiasis, Mucosal.̶= 1; eMedicine from WebMD. [Online] Available: http://emedicine.medscape.com/art= icle/1075227, Oct. 2008.

10.&= nbsp; Kavanagh, Kevin. Oral (Throat) Photographs. World Articles in Ear, Nose, and Throat. [Online] Available: http://www.entusa.com/oral_photos.htm, 2008.

11.&= nbsp; Ghorayeb, Bechara. Picture of Carcinoma of the Alveolar Ridge and Palate. Otolaryngol= ogy Houston. [Online] Available: http://www.entusa.com/oral_photos.htm, Aug. 2007.

12.&= nbsp; Ogundele, Olufunmilayo, Mark Silverberg, and J= ames Foster. “Erythema Multiforme.” eMedicine from WebMD. [Online] Available: http://emedicine.medscape.com/article/762333<= span style=3D'font-weight:normal'>, Feb. 2009.

13.&= nbsp; Chuang, Tsu-Yi, and Laura Stitle. “Lichen Planus.” eMedicine from WebMD. [Online] Available: http://emedicine.med= scape.com/article/1123213, Apr. 2008.

14.&= nbsp; Yousefi, Marjan, et al. “Behcet Disease.” eMedicine from WebMD. [Online] Available: <= strong>http://emedicine.med= scape.com/article/1122381, Feb. 2007.

15.&= nbsp; Kenny, Tim, and Beverly Kenny, eds. “Kawasaki Disease”. Patient UK. [Online] Available: http://www.patient.co.uk/showdoc/40001388, 2008.

16.&= nbsp; Meddles, Katharine, and Vincent Eusterman. “Burning Mouth Syndrome.” eMedicine from WebMD. [Online] Available: http://emedicine.medscape.com/art= icle/1508869